HLA class II histocompatibility antigen, DO alpha chain is a protein that in humans is encoded by the HLA-DOAgene.[1][2]
HLA-DOA belongs to the HLA class II alpha chain paralogues. HLA-DOA forms a heterodimer with HLA-DOB. The heterodimer, HLA-DO, is found in lysosomes in B cells and regulates HLA-DM-mediated peptide loading on MHC class II molecules. In comparison with classical HLA class II molecules, this gene exhibits very little sequence variation, especially at the protein level.[2]
References
↑Young JA, Trowsdale J (Aug 1990). "The HLA-DNA (DZA) gene is correctly expressed as a 1.1 kb mature mRNA transcript". Immunogenetics. 31 (5–6): 386–8. doi:10.1007/BF02115015. PMID2370084.
Piatier-Tonneau D, Gastinel LN, Amblard F, et al. (1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121–8. doi:10.1007/BF00211424. PMID1869305.
Rosenstein Y, Burakoff SJ, Herrmann SH (1990). "HIV-gp120 can block CD4-class II MHC-mediated adhesion". J. Immunol. 144 (2): 526–31. PMID1967269.
Rosen-Bronson S, Long EO (1991). "An unusual form of alternative splicing in the HLA-DNA gene". Immunogenetics. 33 (2): 124–31. doi:10.1007/BF00210826. PMID1999352.
Jonsson AK, Rask L (1989). "Human class II DNA and DOB genes display low sequence variability". Immunogenetics. 29 (6): 411–3. doi:10.1007/BF00375872. PMID2499532.
Clayton LK, Sieh M, Pious DA, Reinherz EL (1989). "Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding". Nature. 339 (6225): 548–51. doi:10.1038/339548a0. PMID2543930.
Diamond DC, Sleckman BP, Gregory T, et al. (1988). "Inhibition of CD4+ T cell function by the HIV envelope protein, gp120". J. Immunol. 141 (11): 3715–7. PMID2846691.
Inoko H, Ando A, Kimura M, Tsuji K (1985). "Isolation and characterization of the cDNA clone and genomic clones of a new HLA class II antigen heavy chain, DO alpha". J. Immunol. 135 (3): 2156–9. PMID2991382.
Andrieu JM, Even P, Venet A (1986). "AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications". AIDS research. 2 (3): 163–74. doi:10.1089/aid.1.1986.2.163. PMID3489470.
Houlgatte R, Scarmato P, el Marhomy S, et al. (1994). "HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4". J. Immunol. 152 (9): 4475–88. PMID7512597.
Chirmule N, McCloskey TW, Hu R, et al. (1995). "HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71)". J. Immunol. 155 (2): 917–24. PMID7541827.
Rowell JF, Stanhope PE, Siliciano RF (1995). "Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC". J. Immunol. 155 (1): 473–88. PMID7602119.
Chen YH, Böck G, Vornhagen R, et al. (1994). "HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41". Mol. Immunol. 31 (13): 977–82. doi:10.1016/0161-5890(94)90092-2. PMID8084338.
Chirmule N, Wang XP, Hu R, et al. (1994). "Envelope glycoproteins of HIV-1 interfere with T-cell-dependent B cell differentiation: role of CD4-MHC class II interaction in the effector phase of T cell help". Cell. Immunol. 155 (1): 169–82. doi:10.1006/cimm.1994.1110. PMID8168144.
Callahan KM, Rowell JF, Soloski MJ, et al. (1993). "HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes". J. Immunol. 151 (6): 2928–42. PMID8376762.
Ruff AL, Guarnieri FG, Staveley-O'Carroll K, et al. (1997). "The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway". J. Biol. Chem. 272 (13): 8671–8. doi:10.1074/jbc.272.13.8671. PMID9079699.
Douek DC, Altmann DM (1997). "HLA-DO is an intracellular class II molecule with distinctive thymic expression". Int. Immunol. 9 (3): 355–64. doi:10.1093/intimm/9.3.355. PMID9088974.